| Issuer | % of Class | Filed | |||
|---|---|---|---|---|---|
|
MapLight Therapeutics, Inc.
13D/A
Amendment 2
MPLT · 56565P103
|
49.9% |
8/18/2026
Event 8/14/2026
|
|||
| Catalyst4, Inc. | 49.9% | ||||
| Robert Brown | 49.9% | ||||
| Ekemini Riley | 49.9% | ||||
| Mark Vorsatz | 49.9% | ||||
|
MapLight Therapeutics, Inc.
13D/A
Amendment 1
MPLT · 56565P103
|
47.9% |
8/3/2026
Event 7/30/2026
|
|||
| Catalyst4, Inc. | 47.9% | ||||
| Robert Brown | 47.9% | ||||
| Ekemini Riley | 47.9% | ||||
| Mark Vorsatz | 47.9% | ||||
|
MapLight Therapeutics, Inc.
13D
MPLT · 56565P103
|
45.1% |
11/20/2025
Event 10/28/2025
|
|||
| Catalyst4, Inc. | 45.1% | ||||
| Robert Brown | 45.1% | ||||
| Ekemini Riley | 45.1% | ||||
| Mark Vorsatz | 45.1% | ||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.